Get the Stockscreener App
5.285
5.28%
0.265
Pre-market:
5.25
-0.035
-0.66%
Candel Therapeutics Inc stock is traded at $5.285, with a volume of 1.27M.
It is up +5.28% in the last 24 hours and up +3.02% over the past month.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
See More
Previous Close:
$5.02
Open:
$5
24h Volume:
1.27M
Relative Volume:
1.61
Market Cap:
$290.14M
Revenue:
$124.00K
Net Income/Loss:
$-49.99M
P/E Ratio:
-3.1272
EPS:
-1.69
Net Cash Flow:
$-31.03M
1W Performance:
+14.39%
1M Performance:
+3.02%
6M Performance:
-5.62%
1Y Performance:
+19.30%
1-Day Range:
$4.97
$5.32
1-Week Range:
$4.38
$5.32
52-Week Range:
$4.25
$14.60
Candel Therapeutics Inc Stock (CADL) Company Profile
Name
Candel Therapeutics Inc
Sector
Industry
Phone
617-916-5445
Address
117 KENDRICK STREET, NEEDHAM
Compare CADL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
5.285 | 275.59M | 124.00K | -49.99M | -31.03M | -1.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-28-25 | Initiated | Stephens | Overweight |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-30-25 | Resumed | H.C. Wainwright | Buy |
| Feb-20-25 | Initiated | Citigroup | Buy |
| Feb-19-25 | Initiated | Canaccord Genuity | Buy |
| Feb-07-25 | Initiated | BofA Securities | Buy |
| Dec-02-22 | Initiated | H.C. Wainwright | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Aug-23-21 | Initiated | Credit Suisse | Outperform |
| Aug-23-21 | Initiated | Jefferies | Buy |
| Aug-23-21 | Initiated | UBS | Buy |
View All
Candel Therapeutics Inc Stock (CADL) Latest News
How Candel Therapeutics Inc. stock trades before earningsJuly 2025 Sentiment & AI Driven Stock Price Forecasts - Newser
Is Candel Therapeutics Inc. stock recession proof2025 Price Targets & Long-Term Capital Growth Strategies - Newser
Is Candel Therapeutics Inc. stock attractive after correctionWeekly Volume Report & AI Forecast for Swing Trade Picks - Newser
Is Candel Therapeutics Inc. stock resilient to inflationPortfolio Update Summary & Safe Capital Investment Plans - Newser
Candel: lighting the path to a brighter future for patients with solid tumors - Nature
Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know - MSN
Candel Therapeutics Stock Headed For 20% Weekly Gains: Retail Over The Moon With BofA's 'Buy' Call - MSN
Candel Therapeutics stock price target raised to $14 by Freedom Capital - Investing.com Nigeria
Will Candel Therapeutics Inc. stock gain from strong economy2025 Price Targets & High Accuracy Trade Alerts - newser.com
What technical models suggest about Candel Therapeutics Inc.’s comebackIndex Update & Safe Entry Zone Tips - newser.com
Why Candel Therapeutics Inc. stock could see breakout soon2025 Earnings Impact & Verified Swing Trading Watchlists - newser.com
How geopolitical tensions affect Candel Therapeutics Inc. stockPortfolio Update Report & Stepwise Trade Signal Guides - newser.com
How Candel Therapeutics Inc. stock performs in stagflationJuly 2025 Earnings & Technical Buy Zone Confirmations - newser.com
Candel Therapeutics Inc. (CADL) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is Candel Therapeutics Inc. building a consolidation baseShare Buyback & AI Powered Market Trend Analysis - newser.com
Candel Therapeutics to host virtual Research & Development event - Proactive Investors
Candel Therapeutics, Inc. Announces Virtual Research and Development Day for December 5, 2025 - Quiver Quantitative
Candel Therapeutics to Host Virtual R&D Event on December 5, 2025 - The Manila Times
Candel Therapeutics (Nasdaq: CADL) Sets Virtual R&D Event on Immuno-Oncology, CAN-2409 and CAN-3110 - Stock Titan
Will Candel Therapeutics Inc. stock benefit from automationJuly 2025 Action & High Accuracy Trade Signal Alerts - newser.com
How Candel Therapeutics Inc. stock compares to growth peersJuly 2025 Highlights & Verified Entry Point Signals - newser.com
What’s next for Candel Therapeutics Inc. stock price2025 Price Action Summary & Safe Entry Zone Tips - newser.com
Will Candel Therapeutics Inc. see short term momentumWeekly Stock Summary & Consistent Profit Trade Alerts - newser.com
Analysts’ Top Healthcare Picks: Candel Therapeutics (CADL), Pfizer (PFE) - The Globe and Mail
Candel Therapeutics Broadens Its Clinical Cancer Studies - Kalkine Media
Citigroup Maintains Candel Therapeutics (CADL) Buy Recommendation - Nasdaq
Candel Therapeutics (CADL) Analyst Rating Update: Citigroup Lowe - GuruFocus
Candel Therapeutics Reports Wider Loss, But Analysts Stay Upbeat - Finimize
Candel pausing development of CAN-2409 in pancreatic cancer type - Seeking Alpha
Candel Therapeutics Inc Stock (CADL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):